Transgene Sa · EURONEXT:TNG
Transgene Sa — Investor Presentation (June 2021)
40 slides from Transgene Sa's investor presentation, Jun 22, 2021
Slide 1: Virus Powered Immunotherapies against Solid Tumors
Virus Powered Immunotherapies against Solid Tumors Corporate Presentation 22 June 2021
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be
Slide 3: A World-Leader in Virus Powered Immunotherapies
A World-Leader in Virus Powered Immunotherapies Click to edit Master title style Ability to Customised Demonstrated Integrated Ability Attractive Transgene’s select and and off-the- induction GMP to conduct technologies technologies engineer shelf products of immune manufacturing clinical could deli
Slide 4: Our Expertise Translates into Two Unique Technology Platforms
Our Expertise Translates into Two Unique Technology Platforms Able Click toto edittarget multiple Master title style solid tumors THERAPEUTIC VACCINE (MVA) Patient specific antigens selected to generate the optimal immune response Vaccinia Immune T cell activation through multi-mechanisms vector • P
Slide 5: Multiple Opportunities to Transform Solid Tumor Therapy
Multiple Opportunities to Transform Solid Tumor Therapy Click to edit Master title Product style Indication Target/Transgene Design Preclinical Phase I Phase II Next step THERAPEUTIC VACCINES Ovarian cancer 1st data 4Q 2021 TG4050 30 neoantigens Head and neck cancers 1st data 4Q 2021 Anogenital HPV+
Slide 6: Individualized Neoantigen Vaccine
Individualized Neoantigen Vaccine Taking the Treatment of Each Patient’s Tumor to a New Level Cutting-Edge Approach one patient • one genome • one vaccine
Slide 7: myvac® | Taking the Treatment of Each Patient's Tumor to a New Level
myvac® | Taking the Treatment of Each Patient’s Tumor to a New Level by Clickcapitalizing onstyle to edit Master title multiple cutting-edge technologies Demonstrated capability of MVA to induce antigen specific immune response – well-established safety profile 2 ongoing clinical trials TG4050: Pati
Slide 8: Producing TG4050, First Clinical Batches Already Released
Producing TG4050, First Clinical Batches of the Individualized Immunotherapy Already Released Click to edit Master title style GMP facility Manufacturing process Current lead-time in place in place and being from tumor biopsy to tailored progressively vaccine shipment in line with automated objectiv
Slide 9: TG4050 | First Individualized Vaccine Based on the myvac® Technology
TG4050 | First Individualized Vaccine Based on the myvac® Technology 2Click ongoing clinical to edit Master trials title style Moderately mutated myvac® tumors MVA Ovarian and Head Established safety & Neck cancers and Limited efficacy of immunogenicity checkpoint blockers DESIGNED TG4050 (low/mediu
Slide 10: TG4050 | Ovarian Cancer Trial after Surgery and Adjuvant Chemotherapy
TG4050 | Ovarian Cancer Trial after Surgery and Adjuvant Chemotherapy Phase I trial Click to edit in title Master 13style patients (NCT03839524) First patient Surgery Asymptomatic relapse enrolled in January 2020 Adjuvant Clinical remission TG4050 (single agent) treatment Platinum chemotherapy | TG4
Slide 11: TG4050 | HPV-Negative Head and Neck Cancer Trial
TG4050 | HPV-Negative Head and Neck Cancer Trial after Surgery and Adjuvant Therapy Randomized Click to edit MasterPhase I trial in 30 patients (NCT04183166) title style Arm First patient Surgery Complete A Recurrence response TG4050 enrolled in single agent Adjuvant Chemo/radio therapy TG4050 + SOC
Slide 12: TG4050 | Next Milestones
TG4050 | Next Milestones Ongoing Click to edit trials – Could Master title style treat patients with an established disease Our strategy is to: Clinical program backed by extensive genomic First clinical and immunologic translational research data from Demonstrate vaccine activity at biological and
Slide 13: TG4001: Potential to Transform the Treatment of Anogenital HPV Positive Solid Tumors
TG4001 Potential to Transform the Treatment of Anogenital HPV Positive Solid Tumors Randomized Phase II trial to start in 2Q 2021
Slide 14: TG4001 | Virus Powered Candidate Vaccine
TG4001 | Virus Powered Candidate Vaccine Click to edit Master title style The right indication The right virus anogenital MVA HPV16-positive cancers Click here OPTIMIZED TREATMENT FOR HPV-POSITIVE TUMORS The right The right HPV antigens patient population E6 and E7 Patients without liver metastasis
Slide 15: TG4001 | Phase Ib/II Data with Avelumab Presented at SITC 2020
TG4001 | Phase Ib/II Data of TG4001 with Avelumab Presented at SITC 2020 Promising results, Click to edit Master particularly in patients without liver metastasis (NCT03260023) title style Collaboration 34 heavily pretreated patients with with metastatic HPV16+ cancer (oropharyngeal, anogenital) Ide
Slide 16: Expanded Trial Focuses on Patient Population with Improved Clinical Benefit
Expanded Trial Focuses on Patient Population that Derived Improved Clinical Benefit in Phase Ib/II Click to edit Master title style Patients with HPV16-positive anogenital cancer including cervical, vulvar, vaginal, penile and anal cancers With recurrent/metastatic disease Treated in first line or i
Slide 17: TG4001 | Randomized Controlled Phase II Trial Supported by Clinicians
TG4001 | Randomized Controlled Phase II Trial Supported by Clinicians Trial to enroll up to ~ 140 patients (NCT03260023) Randomized (1:1) Arm A Patients with TG4001 + avelumab Patients with HPV16+ Anogenital Cancer recurrent/metastatic disease Avelumab single agent Arm B PRIMARY ENDPOINTS SECONDARY
Slide 18: A Methodologically Sound Phase II Trial to Further Validate TG4001
A Methodologically Sound Phase II Trial to Further Validate the Potential of TG4001 Click to edit Master title style Enrollment of first patients in 2Q 2021 Interim analysis data expected around the Trial received regulatory clearance end of 2022 in the US, France and Spain Positive Interim analysis
Slide 19: Our Unique Invir.IO™ Platform
Our Unique Invir.IO™ Platform Rapidly Generating Multiple Virus-Powered Off-the-Shelf Drug Candidates
Slide 20: Invir.IO™ Patented Virus Backbone Based on Vaccinia Virus Copenhagen Strain
Invir.IO™ Patented Virus Backbone Based on Vaccinia Virus Copenhagen Strain KeytotoeditTransformative Click Master title style therapies Tumor-specific replication Safe in a Targeted and Broad spectrum infectivity Accentuated with TK-RR- double deletion large variety Continuous Can infect all types
Slide 21: TG6002 | Chemotherapy Produced Directly in the Tumor
TG6002 | Chemotherapy Produced Directly in the Tumor Interim Click to editPhase I data Master title style (IV*) presented at AACR 2021 The right virus PoC clinical data for IV + payload administration 2 ongoing Phase I/II trials evaluating IV* and Oncolytic armed with FCU1 gene, IHA** administration
Slide 22: TG6002 | Interim Phase I Data Presented at AACR 2021
TG6002 | Interim Phase I Data Presented at AACR 2021 Clinical PoC Click to edit of title Master feasibility of IV route for our patented VVcop TK-RR- virus thestyle TG6002 replicates in tumor 5-FU is expressed in tumor Long-lasting expression tissue without sign of tissue in most of the of 5-FU wide
Slide 23: BT-001 | Oncolytic Virus Encoding for an Anti-CTLA4 Antibody
BT-001 | Oncolytic Virus Encoding for an Anti-CTLA4 Antibody (Ab) Click to edit Master title style Transgene’s patented BioInvent’s potent Invir.IO™ backbone anti-CTLA4 Ab · Oncolysis BT-001 is designed to achieve: · Activates and increases T-effector cells · Anti-tumor immune induction · Treg deple
Slide 24: BT-001 | Phase I/II Trial Starting in Europe
BT-001 | Phase I/II Trial Starting in Europe Leverage the IT* Click to edit Master title route style to accelerate development with anti-PD1 (NCT04725331) Patients with metastatic or Repeated and advanced ascending doses injectable solid Trial authorized of BT-001 IT* tumors such as: in Europe and i
Slide 25: Invir.IO™ Pipeline Will Allow us to Generate Significant Value
Invir.IO™ Pipeline Will Allow us to Generate Significant Value Next Click tocandidates edit Master titleare stylealready in preclinical development Patented Potential to Optimize backbone generate multiple Invir.IO™ value Highly productive creation demonstrated: novel platform via a combination immu
Slide 26: Outlook
Outlook transgene
Slide 27: Financial Visibility until 4Q 2023
Company Funded to Deliver Multiple Value Generating Milestones €19.1 million in cash and cash equivalents at March 31, 2021 Ownership As of May 31, 2021 €34.1 million raised in June 2021 through a private placement In addition, Transgene holds: 62% Tasly BioPharmaceuticals shares valued at €32.3 mil
Slide 28: Our Vision and Environmental, Social and Governance Policy
Our Vision and Environmental, Social and Governance Policy Maintain Company’s Click to edit Master title style Sustainability by Creating Value, Strengthening Social Contribution and Minimizing Environmental Impact Transgene’s ESG strategy is 16 interns based on six commitments 1,883 h 85% permanent
Slide 29: 2021-2022 Milestones
2021-2022 Milestones AClick to editLeader World Master title style in Virus-Powered Immunotherapies against Solid Tumors TG4001 MVA personalised neo-antigen HPV-positive cancers therapeutic VVcopTK-RR- multi-armed oncolytic therapeutic cancer vaccines vaccine viruses TG4050 TG4001 BT-001 Initial Pha
Slide 30: Investment Highlights
Investment Highlights Click to edit Master title style Unique virus A world leader Clinical-stage powered World-class in virus powered immunotherapy technologies scientific and clinical immunotherapies company to specifically target collaborations cancer cells myvac® and Biological and Invir.IO™: be
Slide 31: Thank you for your attention
Thank you for your attention 31
Slide 32: Appendices
Ccpamecrane Appendices
Slide 33: TG6002 | Two Phase I/IIa trials in 5-FU sensitive GI indications
TG6002 | Two Phase I/IIa trials in 5-FU sensitive GI indications Two Click tonovel administration edit Master title style routes - IV and IHA Gastro-intestinal adenocarcinoma with liver Colorectal cancer patients with unresectable metastasis (colon cancer) - TG6002 IV + oral 5-FC liver metastases (C
Slide 34: Multiple Payloads | Deliver Significant Patient Benefits
Multiple Payloads | Deliver Significant Patient Benefits Local Click to payload edit Master delivery title style helps better neutralize the tumor in an effective and safe manner by limiting systemic exposure Targeted insertion of recombinant payload at selected loci in the Vaccinia genome Several I
Slide 35: BT-001 | Exciting Preclinical Data
BT-001 | Exciting Preclinical Data Click to edit Master title style Strong abscopal effect (impact on distant lesions) i.t. injection CT26 Semmrich et al., BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenviro
Slide 36: Ongoing Collaboration with AstraZeneca (AZ)
Ongoing Collaboration with AstraZeneca (AZ) Invir.IO™ platform Click to edit Master validation title style AstraZeneca 5 novel secured an therapeutic Of 5 novel oncolytic payloads to be immunotherapies, Possible option access to integrated in our 2 have been exercise by AZ Transgene’s VVCOPTK-RR- on
Slide 37: TG4050 Process for Individualized Neoantigen Vaccination
TG4050 Process for Individualized Neoantigen Vaccination Combines bioengineering Click to edit Master title style and digital transformation ROUTINE DATA PROCESSING, GENE EDITING, TUMOR BIOPSY GENE SEQUENCING ARTIFICIAL INTELLIGENCE MANUFACTURING Patient Next Selection of Vaccine Treatment generatio
Slide 38: TG4001 | Treatment Induced Long-Lasting Responses and Changes in Micro-Environment
TG4001 | Treatment Induced Long-Lasting Responses and Changes in Clickthe Tumor to edit Master titleMicro-Environment style Evolution of tumor size in patients without liver metastases TG4001 elicits strong, long-lasting and specific T-cell response against HPV16 E6 and E7 Treatment shifts « cold »
Slide 39: Significant Opportunity for TG4001 in Anogenital HPV16-Positive Cancers
Significant Opportunity for TG4001 in Anogenital HPV16-Positive Cancers HPV16 etiology Click to edit creates Master title style a significant market opportunity Incidence of anogenital HPV16 positive cancers w/o liver metastases Newly diagnosed patients with metastatic disease and patients with recu
Slide 40: Contact
C O N TA C T Lucie Larguier Director Investor Relations and Corporate Communication +33 6 7624 7227 larguier@transgene.fr 400 Boulevard Gonthier d’Andernach | Parc d’Innovation | CS80166 67405 Illkirch Graffenstaden Cedex | France Tél.: + 33 (0)3 88 27 91 21 | www.transgene.fr